Tag Archives: Barron039s

Dollar Tree Posts Better-Than-Expected Earnings. Why the Stock Is Falling Sharply. – Barron's

Dollar Tree Posts Better-Than-Expected Earnings. Why the Stock Is Falling Sharply.  Barron’s Dollar Tree Shares Fall as Tariffs Dampen Near-Term Outlook  The Wall Street Journal Dollar Tree, Inc. Reports Results for the Second Quarter Fiscal 2025  Dollar Tree Dollar Tree says higher-income customers are still driving its growth. But the stock is tumbling.  MarketWatch Dollar Tree stock plunges as it warns tariffs will squeeze …

Read More »

Figma’s Earnings Disappointed. The July IPO Is Tumbling. – Barron's

Figma’s Earnings Disappointed. The July IPO Is Tumbling.  Barron’s Figma’s stock plunges after company’s first earnings report since IPO  CNBC Figma Announces Second Quarter 2025 Financial Results  Business Wire Why Figma Stock Lost 39% in August  Yahoo Finance Figma Second-Quarter Revenue Jumps as Businesses Spend More on Design  The Wall Street Journal Source link

Read More »

Nvidia Stock Gains as Earnings Slump Bottoms Out. What Comes Next. – Barron's

Nvidia Stock Gains as Earnings Slump Bottoms Out. What Comes Next.  Barron’s Stock market today: Dow, S&P 500, Nasdaq tumble as rising yields, Trump tariff uncertainty rattle markets  Yahoo Finance Nvidia’s Best Days Look Well Behind Us (NASDAQ:NVDA)  Seeking Alpha What Nvidia’s Earnings Could Mean for Broadcom and Other Chipmakers  Investopedia Nvidia’s $340 Billion Rout Drags Stock Below Key Technical Level  Bloomberg.com Source link

Read More »

Nvidia Stock Falls. Why the Post-Earnings Slump Is Rolling On. – Barron's

Nvidia Stock Falls. Why the Post-Earnings Slump Is Rolling On.  Barron’s Nvidia Is ‘Going To $5 Trillion’ Says Dan Ives, But This Expert Says If ‘AI Turns Out To Be Just A Bubble,’ NVDA May Collapse  Yahoo Finance Nvidia Stock Gains as Earnings Slump Bottoms Out. What Comes Next.  Barron’s What Nvidia’s Earnings Could Mean for Broadcom and Other Chipmakers  Investopedia Nvidia’s $340 Billion …

Read More »

Global Bond Rout Deepens on Worries Over Debt—and Tariffs – Barron's

Global Bond Rout Deepens on Worries Over Debt—and Tariffs  Barron’s 30-year Treasury yield tops 5% briefly as traders deal with tariff uncertainty, Fed independence threat  CNBC Why Long-Dated Bonds Are Falling Out of Favor  Bloomberg.com Bonds selloff keeps investors on edge as gold hits records  Reuters Morning Bid: US long bond yield tests 5% again  Yahoo Finance Source link

Read More »

Trump Tariffs Are Back in Limbo. What Comes Next for the White House, Trade Partners, Companies – Barron's

Trump Tariffs Are Back in Limbo. What Comes Next for the White House, Trade Partners, Companies  Barron’s What Trump’s tariff loss in court means for shippers and the billions in trade duties collected by U.S. government  CNBC Companies could be owed billions of dollars if tariff ruling sticks  Axios Donald Trump Says $15 Trillion Investment In US Will Be ‘Immediately Cancelled!’ If Courts …

Read More »

More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off. – Barron's

More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.  Barron’s Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)  Yahoo Finance Ionis drug lowers triglycerides, reduces pancreas damage in late-stage studies  statnews.com Ionis hits it out of the park with data for Tryngolza in severe blood fat disease  Fierce Pharma Biotech Rockets …

Read More »

Alphabet Stock Jumps After Judge Files Remedy Decisions For Monopoly Case – Barron's

Alphabet Stock Jumps After Judge Files Remedy Decisions For Monopoly Case  Barron’s Google Must Share Search Data With Rivals, Judge Rules in Antitrust Case  The New York Times Alphabet’s stock is rising after Google antitrust ruling avoids the worst-case scenario  MarketWatch Google gets to keep Chrome but is barred from exclusive search deals, judge rules  CNBC Google dodges a $2.5T breakup  Politico Source link

Read More »

Cytokinetics Shares are Jumping. Its Heart Drug Looks Better than Ever – Barron's

Cytokinetics Shares are Jumping. Its Heart Drug Looks Better than Ever  Barron’s Cytokinetics Skyrockets On ‘Provocative’ Results In Heart Disease  Investor’s Business Daily Cytokinetics drug yielded benefits over common therapy in patients with heart condition, study shows  statnews.com Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK)  Seeking Alpha Promising Phase 3 Trial Results Bolster Buy Rating for Cytokinetics’ Aficamten  TipRanks Source link

Read More »